ArticleThe Journal of infectious diseases2011
Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion.
Article in The Journal of infectious diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Camelid VHHs as a Versatile Platform for Combating Viral Infections.Pharmaceuticals (Basel, Switzerland) · 2026Review
- A novel bispecific nanobody protects mice against RSV infection via intranasal administration.Journal of virology · 2025Article
- Review
- Small but Mighty: Nanobodies in the Fight Against Infectious Diseases.Biomolecules · 2025Review
- Unique antibodies across the animal kingdom (birds, camelids, and sharks): therapeutic potential against human respiratory viral infections.Frontiers in immunology · 2025Review
- Single domain antibodies from camelids in the treatment of microbial infections.Frontiers in immunology · 2024Review
- Immunomodulatory nanosystems: An emerging strategy to combat viral infections.Biomaterials and biosystems · 2023Review
- Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models.Communications biology · 2022Article
- Review
- Protein and Peptide Substances in the Treatment of Respiratory Syncytial Infection: Current State.Molecules (Basel, Switzerland) · 2022Review
- Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view.Biochimica et biophysica acta. General subjects · 2021Review
- Nasal delivery of single-domain antibody improves symptoms of SARS-CoV-2 infection in an animal model.PLoS pathogens · 2021Article
- Polyclonal alpaca antibodies protect against hantavirus pulmonary syndrome in a lethal Syrian hamster model.Scientific reports · 2021Article
- Effective high-throughput isolation of fully human antibodies targeting infectious pathogens.Nature protocols · 2021Review
- Single-Domain Antibodies and Their Formatting to Combat Viral Infections.Antibodies (Basel, Switzerland) · 2018Review
- Neutralization of Junín virus by single domain antibodies targeted against the nucleoprotein.Scientific reports · 2018Article
- Passive immunotherapy of viral infections: 'super-antibodies' enter the fray.Nature reviews. Immunology · 2018Review
- Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children.Infectious diseases and therapy · 2018Review
- Nanobodies targeting norovirus capsid reveal functional epitopes and potential mechanisms of neutralization.PLoS pathogens · 2017Article
- Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.Nature communications · 2017Article
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the medical importance of respiratory syncytial virus (RSV) infections, there is no vaccine or therapeutic agent available. Prophylactic administration of palivizumab, a humanized monoclonal RSV fusion (F) protein-specific antibody, can protect high-risk children. Previously, we have demonstrated that RSV can be neutralized by picomolar concentrations of a camelid immunoglobulin single-variable domain that binds the RSV protein F (F-VHHb nanobodies). Here, we investigated the mechanism by which these nanobodies neutralize RSV and tested their antiviral activity in vivo. We demonstrate that bivalent RSV F-specific nanobodies neutralize RSV infection by inhibiting fusion without affecting viral attachment. The ability of RSV F-specific nanobodies to protect against RSV infection was investigated in vivo. Intranasal administration of bivalent RSV F-specific nanobodies protected BALB/c mice from RSV infection, and associated pulmonary inflammation. Moreover, therapeutic treatment with these nanobodies after RSV infection could reduce viral replication and reduced pulmonary inflammation. Thus, nanobodies are promising therapeutic molecules for treatment of RSV.
Indexed as
Identifiers
21998474What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.